Serum miR-9 as a prognostic biomarker in patients with osteosarcoma
Serum miR-9 as a prognostic biomarker in patients with osteosarcoma
复制标题
DOI：
10.1177/0300060514534643
复制
发表时间：
2014-08-01
影响因子：
1.6
通讯作者：
Gao, Zhongli
中科院分区：
文献类型：
--
作者：
Fei, Dan;Li, Yang;Gao, Zhongli
目的：定量检测骨肉瘤患者血清中miR-9的含量，探讨其与骨肉瘤临床病理特征及预后的关系。方法：采用实时定量逆转录-聚合酶链式反应检测骨肉瘤患者和健康对照组血清miR-9的含量。结果：骨肉瘤患者(n=118)血清miR-9水平明显高于健康对照组(n=60)，其表达水平与肿瘤转移分期、肿瘤大小和远处转移显著相关。MiR-9浓度相对较高的患者总体生存时间明显短于miR-9浓度较低的患者。结论：骨肉瘤患者血清miR-9浓度明显高于健康对照组。MiR-9表达上调与肿瘤分期、大小和转移有关。血清miR-9的定量可能是骨肉瘤诊断和预后的有用标记物。
Objectives: To quantify microRNA-9 (miR-9) concentrations in the serum of patients with osteosarcoma; to explore its relationship with clinicopathological characteristics and prognosis of osteosarcoma.Method: Serum miR-9 was quantified via real-time reverse transcription-polymerase chain reaction in patients with osteosarcoma and healthy control subjects. Overall survival was evaluated using the Kaplan-Meier method.Results: Serum miR-9 was significantly upregulated in patients with osteosarcoma (n = 118) compared with healthy control subjects (n=60); its upregulation was significantly associated with advanced tumour-node-metastasis stage, larger tumour size and presence of distant metastasis. Overall survival duration was significantly shorter in patients with relatively high miR-9 concentrations compared with those with relatively low miR-9 concentrations.Conclusions: Serum miR-9 concentrations are significantly increased in patients with osteosarcoma compared with healthy controls. Upregulation of miR-9 is associated with tumour stage, size and metastasis. Serum miR-9 quantification may represent a useful diagnostic and prognostic marker of osteosarcoma.